$NVCT News

Nuvectis Pharma Q1 EPS $(0.26) Beats $(0.32) Estimate

Nuvectis Pharma Files For Mixed Shelf Offering Of Up To $150M

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Q4 EPS $(0.31), Inline

Nuvectis Pharma Initiated Phase 1b Study Of NXP900 In Combination With Astrazeneca's Tagrisso (Osimertinib) In Patients With EGFRmut+ NSCLC

Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma,To Discuss Key NXP900 Preclinical And Clinical Data To Date And Strategy For Monotherapy And Combination Components Of NXP900 Phase 1b Clinical Program At Key Opinion Leader Meeting

Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvectis Pharma Provides Highlights For NXP900 Poster Presentations For 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics In Boston

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvectis To Present NXP900 Clinical Safety And FAT1 Tumor Data At AACR-NCI-EORTC 2025 International Conference

Nuvectis To Present NXP900 Clinical Safety And FAT1 Tumor Data At AACR-NCI-EORTC 2025 International Conference

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900